EGFR and non-small cell lung carcinoma: In this study, we examined the effect of BDMC plus icotinib on primary TKI resistant NSCLC cells, and investigated the underlying molecular mechanism of icotinib sensitization by BDMC in NSCLC cells expressing EGFR wild-type and K-ras mutation or Her2 mutation.